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Radiolabeled leukotriene (LT) Eq was infused into 
three healthy subjects in order to assess the production 
and elimination of sulfidopeptide leukotriene metabo- 
lites in urine. Three different radiolabeled tracers 
were employed, [14,15-3H]LTE4, [3sS]LTEd, and [‘“Cl 
LTE4 in five separate infusion studies. There was a 
rapid disappearance of radioactivity from the vascular 
compartment in an apparent two-phase process. The 
first elimination phase had an apparent half-life of 
approximately 7 min. Radioactivity quickly appeared 
in the urine with lo-16% eliminated during the first 
2 h following intravenous infusion; 7%, 2-5 h; 4%, 5- 
8 h; 4%, 8-15 h; and 1.5%, 15-24 h from the [‘“Cl 
LTE4 experiments. Unmetabolized LTE4 was the major 
radioactive component in the first urine collection, but 
at later times two more polar compounds predomi- 
nated. After extensive purification by normal phase- 
solid phase extraction and reverse-phase high per- 
formance liquid chromatography, these compounds 
were characterized by UV spectroscopy, co-elution 
with synthetic standards, negative ion electron capture 
gas chromatography/mass spectrometry, and tandem 
mass spectrometry. The two major urinary metabolites 
were structurally determined to be 14-carboxy-hex- 
anor-LTE3 and the conjugated tetraene, 16-carboxy- 
A.“-tetranor-LTE 4. Three other minor metabolites 
were detectable in the first urine collection only and 
were characterized by co-elution with synthetic stand- 
ards as l&carboxy-tetranor-LTE3, 18-carboxy-dinor- 
LTE4, and %O-carboxy-LTE4. w-Oxidation and subse- 
quent &oxidation from the methyl terminus appeared 
to be the major metabolic fate for sulfidopeptide leu- 
kotrienes in man. The accumulation of the 14-COOH- 
LTEs and 16-COOH-Al’-LTE4 may reflect a rate-lim- 
iting step in further oxidation of these compounds 
which places a conjugated triene or conjugated te- 
traene, respectively, two carbons removed from the 
CoA ester moiety. Also in the first urine collection 
there was another minor metabolite identified as N- 
acetyl-LTE,, however, no subsequent &oxidation of 
this metabolite was observed. The major metabolites 
of LTE4 might be useful in assessing in uiuo production 
of sulfidopeptide leukotrienes in humans. 
Sulfidopeptide leukotrienes, leukotriene C4/D4/E4, are now 
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known to be the active principles previously referred to as 
slow reacting substances of anaphylaxis (1). These molecules 
are derived from arachidonic acid by action of the enzyme 5- 
lipoxygenase with the intermediate formation of leukotriene 
Aq which is conjugated with glutathione (2-4). Sulfidopeptide 
leukotrienes are synthesized by a variety of cells, for example, 
mast cells (5), eosinophils (6), and macrophages (7) from 
arachidonic acid as well as by transcellular biosynthetic mech- 
anisms from LTAJ1 involving multiple cells such as neutro- 
phils and platelets (8). These molecules possess potent bio- 
logical activities in that they cause profound bronchoconstric- 
tion, vasoconstriction, and increased vascular permeability (9, 
10). Substantial evidence has focused attention on the possi- 
ble role for these eicosanoids in various lung diseases, having 
been detected in bronchoalveolar lavages from atopic patients 
following local challenge with specific antigen as well as in 
bronchial aspirates from patients with acute respiratory dis- 
tress syndrome (11, 12). However, studies evaluating the 
biosynthesis of sulfidopeptide leukotrienes at the level of the 
site of production (i.e. within specific regions of the lung) 
would require the use of invasive techniques. The difficulty 
in sampling the site for synthesis of these molecules has 
focused the attention of several investigators on the possibility 
of identifying metabolites of these molecules in physiological 
fluids such as plasma or urine which might serve as an index 
for the production of these molecules much as do metabolites 
of prostanoids for the synthesis of these active cyclooxygenase 
products of arachidonic acid. 
Detailed information is available concerning the biosyn- 
thetic mechanisms leading to the production of sulfidopeptide 
leukotrienes; however, substantially less is known about the 
biotransformation of these molecules and subsequent elimi- 
nation in the human subject. Leukotriene Cq (LTC,) is known 
to be rapidly metabolized by enzymes present in the plasma 
to the cysteinyl leukotriene Eq (LTE,) by way of the cystei- 
nylglycine active metabolite leukotriene Dq (LTD,) (13). The 
subsequent fate of LTEI has been the subject of several 
investigations. In the rat, LTE, is converted rapidly into N- 
acetyl-LTE4 and the structures of several w- and P-oxidation 
products of N-acetyl-LTE4 from rat hepatocytes has been 
elucidated (14). The occurrence of these metabolites in rat 
bile and in rat urine has also been reported (15). Intravenous 
infusion of [14,15-3H]LTC4 into the human subject resulted 
in the excretion of 12-20% of the radioactivity into urine (16) 
and infusion of [3Hs]LTC4 resulted in more than 40% of the 
radioactivity appearing in the urine (17). In these latter 
1 The abbreviations used are: LT, leukotriene; RP, reverse-phase; 
HPLC, high performance liquid chromatography; PFB, pentafluoro- 
benzene; TxB,, thromboxane; BSTFA, bis(trimethylsilyl)trifluoro- 
acetamide. 
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21772 Human Metabolism of LTE, 
studies, LTE, was identified as a major metabolite excreted 
into the urine; however, a substantial amount of radioactivity 
was associated with compounds more polar and sometimes 
poorly separated by chromatographic means. The aims of the 
ness under reduced pressure and reconstituted in 10 ml of sterile 
saline. The solution was analyzed by ultraviolet spectroscopy in order 
to calculate LTE, concentration. An aliquot was taken for measure- 
ment of radioactivity content by liquid scintillation counting. Each 
volunteer was infused in the right hand dorsal digital vein over a lo- 
min period with LTE, filtered through a 0.22~pm Millex sterile filter 
(Millipore). The actual amount of radiolabeled LTE, infused was 
corrected by subtracting the amount of radioactivity remaining in the 
infusion set and filter which were subsequently washed with methanol 
and measured for radioactivity content: During one experiment with 
f35S1LTE,. samnles of venous blood (2 ml) were taken from the left 
dorsal digital vein of the volunteer every minute (O-10 min) starting 
at the end of the infusion period and then at 20 and 40 min following 
the infusion. These samples were collected in 0.5 ml of heparin, 
rapidly spun in a Microfuge for 1 min at 12,000 x g, and plasma- 
treated with 4 volumes of cold ethanol. The precipitate was separated, 
and supernatant was taken for scintillation counting. Urines were 
collected at 2, 5, 8, 15, and 24 h after infusion, the volume was 
measured, and the radioactivity content was determined by counting 
two different aliquots of the urines. Urine samples from 8-15 h were 
immediately frozen following collection and kept at -20 “C until they 
were taken for purification. All other samples were processed imme- 
diately after collection. 
present investigation were to evaluate the formation of me- 
tabolites from LTE4, infused into human subjects, where a 
radiolabeled tracer which would not be rapidly converted into 
tritium-labeled water was employed. The time course for the 
formation of these metabolites as well as structural charac- 
terization of urinary metabolites was a major focus of this 
study. 
EXPERIMENTAL PROCEDURES 
Subjects and Study Design-This study was approved by the Hu- 
man Research Committee of the University of Colorado Health 
Sciences Center to administer radiolabeled LTE, to normal volun- 
teers. Three healthy male volunteers, aged 35-45 years, were inves- 
tigated. Their weight ranged between 65 and 88 kg. Each subject 
received an infusion of [“C]LTEd, and one was infused upon three 
different occasions with the three different radiolabeled isotopes of 
LTE, employed. 
Materials-Tritiated LTE, [14,15-3H]LTE4 (38 Ci/mmol) was ob- 
tained from Du Pont-New England Nuclear; synthetic LTE, and 
LTA, were obtained from Cayman Chemical (Ann Arbor, MI). ZO- 
Carboxy-leukotriene E, (20-COOH-LTE,), 18-carboxy-19,20-dinor- 
leukotriene E, (18-COOH-LTE,), and 16-carboxy-17,18,19,20-tetra- 
nor-leukotriene E3 (16-COOH-LTE3) were obtained from Oxford 
Biomedical Research (Oxford, MI). N-Acetyl derivatives of LTE, and 
of the different LTE, metabolites were synthesized as described 
below. 14-[“C]Carboxy-15,16,17,18,19,20-hexanor-N-acetyl-LTE~ 
was biosynthesized using [l-i4C]LTE, as the starting material and 
rat hepatocytes as previously described (14). Extraction of urine using 
Amberlite XAD-8 (Supelco, Bellefonte, PA) was performed in a 200- 
ml open column, and Supelclean LC-Si cartridges (Supelco) were 
used for normal phase chromatography. Reverse-phase high perform- 
ance liquid chromatography (RP-HPLC) was carried out using Ultra- 
sphere ODS (5 pm, 0.46 x 25 cm, Beckman), with a 5-pm ODS, 5- 
mm precolumn cartridge (Waters Associates, Millipore Corp.) using 
a binary gradient liquid chromatographic system. Ultraviolet absorb- 
ance spectra were recorded every 2.8 s using a Hewlett-Packard 1040 
photodiode array detector (Hewlett-Packard, Palo Alto, CA). Radio- 
activity from HPLC effluents was measured in some experiments 
using an on-line radioactive monitor (Radiomatic, Tampa, FL) with 
a Flo-stint II (Packard Radiomatic, Tampa, FL) as scintillation 
mixture in a ratio of 3:l. All solvents employed were HPLC grade 
(Fisher), and other reagents were of the highest grade commercially 
available. Bis(trimethylsilyl)trifluoroacetamide (BSTFA) was ob- 
tained from Supelco. Rhodium (5% on alumina powder) and penta- 
fluorobenzyl bromide were obtained from Aldrich. 
Preparation of [“C]LTE, and 135S/LTE~-[Cys-14CO]LTC, (50 
mCi/mmol, obtained from CEA, Saclay, France(l8)) was incubated 
for 3 h at 37 “C with 2 units of y-glutamyltranspeptidase (Sigma) and 
5 units of leucine aminopeptidase (Sigma) in 1 ml of Hanks’ balanced 
salt solution. Four volumes of cold ethanol was added to precipitate 
proteins, and, following centrifugation, the supernatant was purified 
by RP-HPLC using methanol/water/acetic acid (70:30:0.02, v/v/v) 
(system I) as an isocratic mobile phase. Fractions which co-eluted 
with synthetic LTE, were pooled and stored at -70 “C before use. 
[36S]LTCd was prepared biosynthetically from [?S]cysteine (600 
Ci/mmol, Du Pont-New England Nuclear Boston, MA)-labeled hu- 
man platelets. Human platelets were obtained from 80 ml of platelet- 
rich plasma and prepared following previously described procedures 
(19):Resulting platelets were suspended in 5 ml of citrate buffer, pH 
6.5. containing PGE, (19). Platelets were incubated with 1 mCi of L- 
[36S]cysteine.After 180 min at room temperature, the cells were 
washed twice and then resuspended at 0.5 x lO’/ml in Hanks’ 
balanced salt solution containing 0.5% bovine serum albumin. LTAh 
(10 fiM) was then added, and the incubation was carried out for 30 
min at 37 “C. At the end of the incubation, y-glutamyltranspeptidase 
(2 units) and leucine aminopeptide (5 units) were added for an extra 
30 min. Two volumes of ice-cold methanol was then added. After 60 
min at -20 ‘C, the precipitated proteins and cells were pelleted. The 
supernatant was taken to dryness and reconstituted in 20% methanol 
in water, and [“S]LTE, was isolated by RP-HPLC using system I. 
Infusion of Labeled LTE4-Radiolabeled LTEl was taken to dry- 
Purification of Metabolites from Urine-Each urine sample was 
acidified to pH 4 with formic acid and then applied to an exaustively 
washed XAD 8 column (20). The column was then washed twice with 
200 ml of water, and the radioactivity eluted with 200 ml of methanol. 
Radioactivity not retained by the column, but eluted in the water 
washes, was determined. The methanolic eluate was dried under 
reduced pressure (0.1 torr) and reconstituted in 15% methanol/water 
for injection on a RP-HPLC using a linear gradient from 16 mM 
ammonium formate made pH 4.8 with HCI to methanol/water/acetic 
acid (90:10:0.1, v/v/v) over 55 min (system II). The effluent of a 
separate aliquot (5-20%) was analyzed with an on-line radioactive 
monitor for determination of the metabolic profile of each timed urine 
sample. The remaining urine sample was purified by an identical RP- 
HPLC system and 1-min fractions were collected. Designation of 
metabolites refers to retention time on this HPLC separation step 
(Hxx; H = human; xx = retention time in minutes). Those fractions 
which contained significant amounts of radioactivity were then taken 
to dryness, reconstituted in 4 ml of methanol/ethyl acetate (50:50, 
v/v), and applied to a normal phase cartridge prewashed with 4 ml of 
CH&l,, 4 ml of methanol, and 4 ml of ethyl acetate. The cartridge 
was then washed with 4 ml of methanol/ethyl acetate (7:3, v/v) and 
eluted with 4 ml of methanol/water/formic acid (95:5:0.1, v/v/v). This 
latter fraction was dried under reduced pressure, reconstituted in 15% 
methanol and injected onto RP-HPLC using a methanol/water/acetic 
acid mixture adjusted to pH 6 with ammonium hydroxide as an 
isocratic eluting system. The exact composition was 15:85:0.02 (v/v/ 
v) for H31 and 25:75:0.02 (v/v/v) for H36. H60 was purified using 
system I, and H40, H45, H50,‘and H58 were not subjected to this 
purification step. The amount of radioactivity present in each fraction 
was determined from a small aliquot taken from l-min fractions. 
Final purification (system III) and co-elution with biological and 
synthetic standards were performed with RP-HPLC using a linear 
gradient from 3.2 mM ammonium formate made at pH 4 with HCl 
Isolvent A) to a mixture of solvent A in acetonitrile (solvent B). For 
the metabolites H31. H36. H40. and H45. solvent B was 1:l (solvent 
A/acetonitrile, v/v),‘and the gradient lasted 55 min. For metabolite 
H50, solvent B was 64 (v/v)and the gradient was over 30 min; for 
H58 and H60, solvent B was 60:40:0.02 formic acid (v/v/v), and the 
gradient was over a 25-min period. 
Acetvlution Conditions-The acetvlation of metabolite H31 and 
other standards was carried out in i50 ~1 of ethanol following the 
addition of 80 mM sodium bicarbonate, 150 ~1 of triethanolamine (80 
mM water), and 10 $1 of acetic anhydride (10% in ethanol). The 
reaction was allowed to proceed for 30 min at 4 “C, then stopped with 
4 ml of water. The reaction mixture was acidified with formic acid 
and applied to a Sep-Pak cartridge (Waters Associates) conditioned 
with 5 ml of methanol and 5 ml of water. After washing with 
additional 5 ml of water following application of the sample, the N- 
acetylated compounds were eluted with 4 ml of methanol. All deriv- 
atives were stored at -70 “C. 
Moss Spectrometry-Aliquots of metabolites obtained from the 
final HPLC nurification were subjected to catalytic desulfurization 
using 5% rhodium on alumina. Briefly, the samples were dissolved in 
1 ml of 50% methanol/water and 5-10 mg of Rh/Al,O,, which had 
been prewashed with methanol, was added. Hydrogen gas was slowly 
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Human Metabolism of LTE, 21773 
bubbled through the solution for 30 min followed by treatment with 
50 ~1 of 1 N NaOH. The sample was centrifuged to a separate catalyst, 
and the supernatsnt was acidified with a drop of formic acid and 
extracted with 2 volumes of ethyl acetate. The organic layer was 
taken to dryness under a stream of dry nitrogen and treated with 
10% NJ-diisopropylethylamine and 10% pentafluorobenzylbromide 
in acetonitrile for 20 min at room temperature to yield the pentafluo- 
robenzyl ester. Any hydroxyl groups present in the metabolite re- 
maining following the hydrogenation step were converted into the 
trimethylsilyl ether derivative by reaction with BSTFA (1:l in ace- 
tonitrile) for 15 min at 60 ‘C. Products were analyzed by gas chro- 
matography-mass spectrometry (Finnigan SSQIIO, San Jose, CA). 
Capillary gas chromatography was carried out using a splitless injec- 
tor at 280 “C, and the column temperature programmed from 200- 
300 “C at 15 “C/min. The capillary column employed was a DB-1 
column, (10 m x 0.25 mm inside diameter, 0.2-pm film thickness; 
J&W Scientific, Bsncho Cordova, CA). The mass spectrometer was 
operated in a negative ion electron capture (chemical ionization) 
mode using methane as moderating gas at 0.5 torr. A mixture of C- 
19 through C-27 fatty acids derivatized to pentafluorobenzyl ester 
was used to determine the carbon number equivalent for each reduced 
and derivatized metabolite. The number of carbons of the various 
fatty acyl groups of these standard PFB derivatives was plotted 
against the measured retention time using the above described con- 
ditions. The resulting linear regression (r = 1.0) was used to calculate 
the carbon number equivalent for each metabolite. 
Tandem mass spectrometry was carried out on a Finnigan TSQ- 
70B mass spectrometer (Finnigan Corp., San Jose, CA). The GC and 
source conditions were the same used with the mass spectrometric 
experiments described above with argon as collision gas in the second 
quadrupole field region with an energy of 30 eV (laboratory frame of 
reference). 
RESULTS 
No adverse effects were observed in any of the volunteers 
during the infusion of LTE.+ The amount of LTE, infused 
into each subject (Table I) ranged from 2.4 to 45 rg and the 
radioactivity from 0.25 to 4.0 &i. The amount of radioactivity 
recovered in the urines appeared to be related to the type of 
radiolabeled tracer LTE., employed and ranged during the 
first 24 h after infusion between 30 and 44% when [‘“Cl- or 
[36S]LTE4 was employed, but was only 9.9% when [14,15-3H] 
LTE, was used (Table II). While there was a 6-fold difference 
in the absolute quantity of LTE, injected in those experiments 
involving [14C]LTE4, there was only a slight difference in the 
total percentage of radioactivity recovered in the urine during 
a 24-h period. This suggested that there was no relationship 
between the amount of LTE, infused and the percent excre- 
TABLE I 
Radiolabeled tracers employed in human metabolism studies 
Volunteer Weight LTE, tracer Amount Injected 
kg pCi Es 
N. V. 80 ‘T 0.25 2.5 
J. M. 65 14C 1.5 15 
R. M. 88 W 0.36 3.6 
%3 4 45 
3H 2.1 2.4 
TABLE II 
Time course for appearance of radioactivity in collected urines 
Values as percent of the total radioactivity infused. 
3H MC” 53 
o-2 7.3 13.4 13.6 
2-5 1.8 7.5 12 
5-8 0.8 4.3 5.7 
8-15 NDb 4.3 7 
15-24 ND 1.5 6 
Total 9.9 30.0 44.3 
a Average of three subjects. 
b ND, not detectable. 
tion of LTE4 metabolites at the doses employed. 
As seen in Fig. 1, the disappearance of [35S]LTE, from the 
vascular compartment was rapid during the first 10 min 
following infusion of one individual. Using the early time 
points of the curve of disappearance of radiolabel from 
plasma, the half-life of LTE, in plasma was estimated to be 6 
to 7 min. This suggested that an efficient mechanism for the 
uptake of LTE4 from blood and removal from the venous 
compartment exists. The time course for appearance of radio- 
active metabolites in three subjects is shown in Table IV and 
for one subject infused with [35S]LTE4 in Table V. For all 
individuals, the LTE, was most abundant in the first urine 
collection (2 h) dropping to one-tenth of that value by the 
second urine collection (3 h). After 5 h following infusion, no 
radiolabeled LTE, was detectible. There also appeared to be 
a second elimination phase of substantially longer duration 
perhaps related to the appearance of metabolites in plasma 
and their subsequent removal by excretion from the kidney 
into the urine. 
Metabolite Purification-The extraction of acidified urine 
using Amberlite XAD-8 resulted in a substantial amount of 
radioactivity being retained by the column which could be 
subsequently eluted with methanol. The relative amount of 
extractable radioactivity decreased with time of urine collec- 
tion, ranging from 63 to 80% of the radioactivity in urine 
during the O-2-h collection period to 26 to 42% in those urines 
collected between 15 and 24 h after infusion (Table III). This 
suggested that more polar metabolites not retained by the 
XAD-8 column were being formed and eliminated in urine as 
time following the infusion period increased. 
Analysis of the methanol eluate from XAD-8 of the first 
urine collections (O-2 h) always revealed a major radioactive 
peak at the retention time of synthetic LTE, (H60); however, 
several other peaks were also observed (H58, H50, H46, H40, 
H36, and H31) in substantially less amounts (Fig. 2A). XAD- 
8-retained material from the second urine collection (2-5 h) 
=S-LTE, 
FIG. 1. Disappearance of radiolabel from plasma after in- 
travenous infusion with 4 &i of [?3]LTE., into one normal 
volunteer (R. C. M.). Inset, log transformation of plasma radioac- 
tivity and linear regression of values between 1 and 10 min. 
TABLE III 
Distribution of urinary radioactivity from [‘V]LTE4 
following XAD-8 extraction 
Results are averages of three subiects. 
Hz0 MeOH 
Amount in Total injected Amount in urine urine Total injected 
% % 
o-2 26.2 3.8 73.8 9.6 
2-5 40.1 3.1 59.9 4.4 
5-8 47.8 2.1 59.2 2.2 
8-15 60 2.8 40 1.5 
15-24 67.4 1 32.6 0.5 
Total 12.8 18.2 
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B 
2-shl I+31 
l-m 
Ii60 
A iJY++ ?I 
0 10 20 30 40 50 60 
Retention Time (mud 
FKG. 2. Reverse-phase HPLC (system I) separation of meth- 
anol eluate from the XAD-8 extraction. A, sample from the first 
urine collection, 0 to 2 h after the infusion with [35S]LTE4. The 
lettered labels indicate the expected retention times for synthetic 
standards separated by this RP-HPLC system as follows: a, LTE,; b, 
N-acetyl-LTE4; c, 20-COOH-LTE,; d, 1%COOH-LTE4; and e, 16- 
COOH-LTE3. B, sample from the second urine collection, 2 to 5 h 
after the infusion with [35S]LTE4. Radioactive metabolites designated 
as per HPLC retention time. 
TABLE IV 
Appearance of human metabolites of LTE4 in timed urine samples 
following infusion with [“C]LTE, into three separate human subjects 
Values are means + S.E.; n = 3. 
[“CILTE, injected 
O-2 h 
2-5 h 
5-8 h 
8-15 h 
Total in urine 
H60 H36 H31 
% 
6.7 f 0.7 1.0 + 0.9 0.7 + 0.5 
0.5 + 0.2 2.1 +- 0.6 1.4 2 0.3 
1.3 t 0.1 0.1 + 0.1 
0.6 + 0.5 0.4 f 0.3 
7.2 + 0.8 5.0 + 1.3 3.2 f 0.5 
typically revealed little radioactivity at the retention time of 
LTEI, with two separated peaks accounting for the majority 
of the radioactivity in these samples (Fig. 2B). These peaks 
(H31 and H36) were clearly detectable in all subsequent urine 
samples up to 15 h after infusion and together accounted for 
more than 8% of the total infused radioactivity (Table IV). 
Other metabolites were virtually undetectable following the 
5-h time period of urine collection. The time course for 
appearance of radioactive metabolites from [14C]LTE4 aver- 
aged for three subjects is shown in Table IV and for one 
subject infused with [%]LTE4 in Table V; 5 h after infusion, 
no radiolabeled LTE, was detectable in any subject. The major 
metabolites had a different and prolonged elimination time 
course typified in Table V with maximal excretion between 2 
and 5 h following infusion. Only in one subject (J.M.) of the 
five infusion studies was there some alteration in the time 
course shown in Table V. This individual had a prolonged 
urinary excretion period of radioactive metabolites that was 
fairly constant during each of the first three collection periods 
(8 h). There were no major differences in the appearance of 
these more polar human metabolites of LTE, when W- or 
35S-labeled LTE, was employed as tracer. However, these 
TABLE V 
Recovery of f?Y]LTE, and radiolabeled metabolites in partially 
purified urine from one human subject (R. M.) 
Values are means + S.E.; n = 3. 
Injected LTE, 
O-2 h 
2-5 h 
5-8 h 
8-15 h 
Total 
H60 H36 H31 
% 
7.3 (3300 ng) 0.6 (280 ng) 1.3 (590 Ilg) 
0.8 (360 ng) 1.4 (610 ng) 2.1 (940 ng) 
0.6 (280 ng) 0.7 (310 ng) 
0.4 (180 ng) 0.5 (230 ng) 
8.1 (3660 ng) 3.0 (1350 ng) 4.6 (2070 ng) 
A 
H31 !A- 
c H50 
/ *da 280 280 300 320 !240240 2110 280 300 320 %a 
Wavelength (nm) 
FIG. 3. UV absorption spectra of human LTE, metabolites. 
A, metabolite H31; B, metabolite H36; C, metabolite H58; D, metab- 
olite H60. 
metabolites were totally absent in all urine samples collected 
from the volunteer using [14,15-3H]LTE4 as tracer. Corre- 
spondingly, the amount of radioactivity present in the urine 
samples from the tritium tracer experiment almost coincided 
with the amount of LTE, present in urine, the small differ- 
ences represented by H40, H46, H50, and H58 was detectable 
in the first urine collection. These results are in agreement 
with those previously published in two other human experi- 
ment studies (16,17). Thus, it would appear that these major 
metabolites of LTE4 involved metabolism which led to ex- 
change of the protons on carbon 14 and carbon 15 to remove 
this tracer from the metabolite structure. Full ultraviolet 
spectra were obtained for four of the human urinary metab- 
olites as these molecules eluted from the HPLC (system III) 
and are shown in Fig. 3. 
Metubolite HGO-Urinary metabolite designated H60 eluted 
at the retention time of synthetic LTE4 as mentioned above. 
It had a UV spectrum consistent with the injected LTE4 (Fig. 
30). Furthermore, this metabolite co-eluted with authentic 
LTE, in two separate HPLC systems involving different 
mobile phases (system I and system III). FAB mass spectrom- 
etry revealed an ion at m/z 438 (M - H)- which, by tandem 
mass spectrometry and collision-induced dissociation, decom- 
posed to ions at m/z 115,235,333, and 351 identical with that 
observed for synthetic LTE4. Therefore, metabolite H60 was 
identified as unmetabolized LTE4. Concerning the two differ- 
ent RP-HPLC systems used, it is important to note that the 
acetonitrile/water (system III) mobile phase was substantially 
different from the methanol/water (system I) mobile phase, 
eluting N-acetyl derivatives later rather than prior to the 
corresponding nonacetylated compound. 
Metubolite H36-The urinary metabolite H36 had a unique 
ultraviolet absorption spectrum with maximum absorbance 
at 306 nm with shoulders at 295 and 318 (Fig. 3B). A similar 
UV absorption spectrum was seen for rat metabolite E which 
corresponded to 16-COOH-A13-N-acetyl-LTE4. Reduction of 
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H36 using rhodium on alumina followed by derivatization as 
the pentafluorobenzyl ester trimethylsilyl ether resulted in a 
derivative which could be analyzed by electron capture GC/ 
maining portion of the molecule has not been altered from 
that found in LTE,. 
Metabolite H31--The least lipophilic major metabolite had 
a UV spectrum typical of a sulfidopeptide leukotriene con- 
taining a thioether bond allylic to the conjugated triene with 
UV maximum at 277 nm and shoulders at 267 and 290. 
Desulfurization of this metabolite using rhodium on alumina 
and subsequent conversion to the pentafluorobenzyl ester 
trimethylsilyl ether derivative yielded a compound analyzed 
by electron capture gas chromatography/mass spectrometry. 
The retention time of this derivative (expressed as carbon 
number equivalents) was 23.45 (Table VI), exactly 2 car- 
bon eq lower than the retention time of standard 1,16- 
MS. The retention time, expressed as carbon number equiv- 
alent, of the major component obtained following reduction 
and derivatization was 25.45 (Table VI). The mass spectrum 
(negative ion electron capture) of this metabolite (Fig. 4B) 
showed abundant ion at m/z 553, corresponding to the car- 
boxylate anion. The retention time and mass spectral be- 
havior was identical with that obtained from 1,16- 
bis(pentafluorobenzyl)-5-trimethylsiloxyhexadecanedioate 
obtained from reduction of synthetic 16-COOH-LTEZ (15). 
Due to losses suffered during each purification step, the 
amount of this metabolite obtained from human urine for 
mass spectral studies was less than 40 ng, and the less abun- 
dant ions in the authentic mass spectrum of this derivative 
could not be seen above the instrument noise level as shown 
in Fig. 4B. However, the RP-HPLC retention time of metab- 
olite H36 in three different HPLC systems does not corre- 
spond to the retention time of the synthetic 16-COOH-LTE3, 
but the UV data indicated that a thioether sulfur atom was 
still allylic to a conjugated tetraene as the chromophore. These 
observations were consistent with identification of metabolite 
H36 as 16-carboxy-17,18,19,20-tetranor-A’3-LTE4. The exact 
stereochemistry of this metabolite has not been investigated 
due to the limited quantities available for further study. The 
geometry of double bond at C13-14 in particular is not known; 
however, it is assumed that the stereochemistry of the re- 
FIG. 4. Negative ion electron capture mass spectrum of the 
PFB, trimethylsilyl derivatives obtained from 5-hydroxy- 
l,l&hexadecanedioic acid obtained by catalytic desulfuriza- 
tion starting from 500 ng of synthetic 16-COOH-LTE3 (A) 
and metabolite H36 after catalytic desulfurization starting 
from a maximum of 20 ng of HPLC-purified human urinary 
metabolite (B). 
TABLE VI 
Gas chromatographic equivalent 
Carbon number values for 
standards and metabolites” 
5-Hydroxy-1,16-hexadecanedioic acid 25.45 
Metabolite H36 (reduced) 25.45 
Metabolite H31 (reduced) 23.45 
a As the pentafluorobenzyl ester, trimethylsilyl ethers; capillary 
column, DB-1 (10 m x 0.25 mm inside diameter, 0.2-pm film thick- 
ness) .
A H31 
B 327 
MS/MS w-III-I- 
525 
M/Z 525 
FIG. 5. Negative ion electron capture mass spectrum of the 
PFB, trimethylsilyl derivative obtained from metabolite H31 
after catalytic desulfurization starting from 100 ng of HPLC- 
purified human urinary metabolite (A) and collisional acti- 
vated decomposition of m/z 525 obtained in spectrum 5A by 
tandem MS/MS (B) . 
0 s 10 1s 20 2s 30 
RETEH~ON rite (UN) 
FIG. 6. Reverse-phase HPLC (system III) separation of me- 
tabolite H31 and metabolite F (14-carboxy-15,16,17,18, 
19,20-hexanor-N-acetyl-LTEs from rat hepatocytes incu- 
bated with [W]LTE.,) (A) and metabolite H31 (after N-acet- 
ylation carried out as described under “Experimental Proce- 
dures”) and metabolite F. 
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FIG. 7. Comparison of retention 
behavior of metabolite H40 and - 
Human Metabolism of LTE, 
A 
6 Pg of synthetic 16-carboxy- 
17,18,19,20-tetranor-LTEs (A) and 
metabolite H46 and 5 pg of synthetic 
l&carboxy-19,20-dinor-LTEb un- 
der certain conditions of reverse 
phase-HPLC (system IV) (B). 
B 
bis(pentafluorobenzyl)-5-trimetbylsilyloxyhexadecanedioate 
obtained from reduction of synthetic 16-COOH-LTE3. The 
mass spectrum of this metabolite is shown in Fig. 5A and 
presents abundant ions at m/z 525 (M - 181), corresponding 
to the carboxylate anion of a monohydroxytetradecandioic 
acid derivative. The ions at m/z 435, loss of trimethylsilanol 
from M - 181, further support the presence of a monohydroxy 
group derivatized as the trimethylsilyl ether. Collision-in- 
duced decomposition of the ion at m/z 525 in a tandem 
quadrupole mass spectrometer yielded a unique ion at m/z 
327 corresponding to the loss of pentafluorobenzyl alcohol 
indicating the presence of a second PFB-derivatized carboxyl 
(Fig. 5B). This M - 198 ion is the unique ion also observed 
in the CAD spectra of authentic, derivatized B-hydroxyhex- 
adecandioic acid. As shown in Fig. 6, co-injection of metabolite 
H31 with rat metabolite F (14-carboxy-N-acetyl-LTE3) re- 
sulted in clearly separable components between the rat hep- 
atocyte metabolite and the human urinary metabolite, even 
though the rat metabolite F consisted of two components in 
this HPLC system. These two components were most likely 
the 11-trans-14-COOH-N-acetyl-LTE3 and 14-COOH-N-ace- 
tyl-LTEa derivatives, respectively, as indicated by the shift to 
lower wavelengths of the UV spectrum of the former com- 
pound. When the human metabolite H31 was acetylated using 
conditions to acetylate only free amino groups, the N-acety- 
lated human metabolite then co-eluted with the rat metabolite 
14-carboxyl-N-acetyl-LTE3. Thus, metabolite H31 was con- 
sistent with the structure 14-carboxy-15,16,17,18,19,20-hex- 
anor-LTE3. The exact stereochemistry of this metabolite has 
not been investigated, but it is assumed to be unaltered from 
that found in LTE4. 
Metabolite H58 and Minor Metabolites-The ultraviolet 
spectrum of metabolite H58 revealed the typical sulfidopep- 
tide leukotriene spectrum with absorption maximum at 280 
nm and shoulders at 270 and 292. Furthermore, this metabo- 
lite co-eluted with standard N-acetyl-LTEl in two HPLC 
systems involving methanol/water and acetonitrile/water as 
mobile phases (system I and system III). 
Insufficient material was available to obtain ultraviolet 
spectra for metabolites H40, H46, or H50. However, each of 
these metabolites as measured by radioactivity co-eluted with 
synthetic standards as shown in Fig. 7. These metabolites 
corresponded to 16-COOH-LTE3 (H40), 18-COOH-LTE4 
(H45), and 20-COOH-LTE4 (H50) (data not shown). 
DISCUSSION 
Following discovery of the sultidopeptide leukotrienes over 
a decade ago, there has been a considerable amount of interest 
concerning the biological role that these potent metabolites 
of arachidonic acid may play in human physiology and patho- 
physiology. A primary role for these molecules as lipid media- 
tors requires mechanisms for inactivation and elimination 
from the organism. LTC, is known to be rapidly converted 
into LTD, and LTE, by various peptidases present in cells as 
well as tissues including blood. Furthermore, all sulfidopeptide 
leukotrienes were shown to have energy-dependent uptake 
mechanisms in the liver (21). Previous human studies using 
tritium-labeled LTE, revealed rapid elimination from the 
blood and appearance of significant radioactivity in urine. Of 
interest is the observation reported in this study of the im- 
portance of the position and type of radiolabeled tracer em- 
ployed in determination of the exact amount of radiolabeled 
metabolites appearing in urine. Sulfur 35-labeled LTE, was 
recovered in the highest amounts in urine as opposed to LTE, 
labeled with two tritium atoms attached to the 14,15-double 
bond that resulted in only 10% recovery of radioactivity in 
the urine. These data suggest that a major metabolite pathway 
for LTE, results in removal of protons at carbons 14 and 15 
of the original arachidonic acid backbone. 
The results from this study also support the observation 
that LTE, is rapidly removed from blood and eliminated via 
urine as an intact molecule within the first 2 h (16, 17, 22). 
Subsequent to that, however, LTE4 is a minor component and 
other metabolites of LTE* predominate. When using “C- and 
36S-labeled LTE4, it became evident that these more polar and 
less lipophilic metabolites are excreted in amounts that exceed 
the elimination of unmetabolized LTE,. This would suggest 
that they may play an important role in assessing in uiuo 
sulfidopeptide leukotriene biosynthesis. 
In studies with isolated rat hepatocytes, LTE4 was previ- 
ously shown to be initially metabolized into N-acetyl-LTE4 
which was a substrate for w-oxidation followed by a series of 
sequential /3-oxidation transformations (14). Major metabo- 
lites formed include the 16-COOH-N-acetyl-LTES which re- 
sulted following the action of 2,4-dienoyl-CoA reductase (23) 
on the 18-COOH-N-acetyl-LTE4 CoA ester intermediate in 
the @oxidation cycle. Just as @-oxidation is recognized to be 
a major route of metabolism of prostaglandins from the car- 
boxy1 terminus (24), the major route of metabolism of the 
sulfidopeptide leukotrienes involves p-oxidation from the 
methyl terminus following an initial w-oxidation. Structures 
of the human metabolites identified by ultraviolet spectros- 
copy and mass spectrometry are shown in Fig. 8. These 
structures suggest that a major pathway for LTEd metabolism 
in humans involves an initial w-oxidation to PO-hydroxy-LTEr 
 at Università degli studi di M
ilano, on June 29, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Human Metabolism of LTE, 21777 
LTE, N-axtyl 
HSO 
Tranaforaao 
ZO-COOH-LTE, 
B 
FIG. 8. Proposed pathway for 
LTE, metabolism in human subjects. 
The exact stereochemistry of the new 
structurally characterized metabolites 
has not been established (see text). 
N-AC-LTE, 1%COOH-LTE, 
H36 tOOH 
16-COOH-&LTE, 
H31 COOH 
14-COOH-LTE, 
followed by oxidation to PO-carboxy-LTEd. A small amount 
of N-acetyl-LTE, was observed in the urine of all volunteers; 
however, none of the subsequent w/@-oxidized metabolites 
involve the N-acetyl group. This is consistent with the pro- 
posed pathway for the metabolism of LTE, in monkeys in 
which the 20-hydroxy- and 20-COOH-LTE4 metabolites were 
observed. In human subjects, continued metabolism via &- 
oxidation of 20-carboxyl-LTE., leads to the accumulation of 
two metabolites, the 16-COOH-A13-LTE4 (H36) and the 14- 
COOH-LTE, (H31). Minor amounts of the 16-COOH-LTE3 
were also observed suggesting the importance of 2,4dienoyl- 
CoA reductase in human metabolism of LTE+ While not 
indicated in Fig. 8, which shows the identified structures, 
these reactions proceed as the CoA esters of the carboxyl 
group starting at the C20 terminus. 
The accumulation of ll-carboxy-LTEB suggests a limiting 
step in further @-oxidation of this metabolite which places the 
conjugated triene now two carbons removed from the CoA 
ester moiety in the p-oxidation complex. Further steps of /3- 
oxidation would involve some stage of reduction of the triene 
in order to continue the cleavage of two carbon fragments 
through a thiolase-mediated reaction. The biochemical steps 
involved in such reactions are poorly understood at the pres- 
ent time. A similar situation exists for the further metabolism 
of the 16-carboxyl-tetraene metabolite which would now place 
a conjugated tetraene two carbons removed from the CoA 
ester. Interestingly, the formation of the tetraene metabolite 
was not observed when [3H]LTE, was used as the radiolabeled 
tracer in this study or in previous human studies (16, 17). As 
noted in the metabolism of LTE, in the isolated rat hepatocyte 
(14), the specific activity of the tetraene metabolite (metabo- 
lite E) was substantially reduced over the starting material 
suggesting that exchange of the protons on carbons 14 and 15 
occurred during the mechanism of formation of this tetraene 
metabolite in the rat,. As previously suggested, this might 
involve oxidation of the 16-COOH-LTE3 metabolite (as the 
CoA ester) into the A-2,3 unsaturated intermediate, for ex- 
ample, catabolized by peroxisomal acyl-CoA oxidase (25) fol- 
lowed by the action of cis,trans-3,2-enoyl-CoA isomerase 
working reversibly. This mechanism would account for ex- 
change of these exact protons with water and thereby loss of 
the tritium label from [~~J~~H]LTE~ in human metabolism 
studies. 
The appearance of radiolabeled LTEb metabolites in the 
three subjects investigated was remarkably similar in terms 
of the abundance of each of the reported major metabolites. 
However, it should be noted that all three subjects were 
healthy males of similar age. It is not known whether any of 
these subjects were slow or fast acetylators (26) and whether 
acetylation phenotype plays any significant role in the ap- 
pearance of N-acetyl-LTEl and related metabolites. 
The absolute amount of the LTE, metabolites eliminated 
in urine is similar to that observed for the major metabolites 
of prostaglandins which are routinely measured as an index 
of prostanoid production in uiuo (27). For example, the major 
metabolites of thromboxane, either 2,3-dinor-TxB2 or ll- 
dihydro-TxBz represent 6-7% each of the fractional conver- 
sion of exogenously administered low doses of TxB2 (28). The 
H31 and H36 metabolites of LTEs reported in this study 
appear in urine in similar concentrations to these prostanoid 
metabolites. 
Nevertheless, measurement of the @-oxidation metabolites 
of LTE, would eliminate potential problems associated with 
kidney LTE, production and elimination. For example, meas- 
urement of TXBZ and prostaglandin Et in urine reflects kidney 
production of these metabolites rather than whole body pro- 
duction of these prostaglandins. We suggest that measure- 
ment of the major LTE, metabolites structurally character- 
ized here might better reflect total body production of sulfi- 
dopeptide leukotrienes. 
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